Under way, not recruiting
De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell Carcinoma
NCT04638465 · Nebraska Methodist Health System · Updated 9 Nov 2023
- What is being tested
- Transoral robotic surgery; Cisplatin - Dose Level 1; Cisplatin - Dose Level 2; Dose Level 1; Dose Level 2
- For
- HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage; Oropharynx Cancer
- Kind of study
- Watches patients without assigning a treatment. No drug phase (a device or procedure study).
- Who can join
- Ages 19 years and older. About 150 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started 6 Aug 2018, ends Jan 2030. Registered 20 Nov 2020.
- Results
- None posted yet.
In the researchers' words
The purpose of this study is to evaluate the effects, good and/or bad, of treating participants with HPV-mediated oropharyngeal cancer, with less treatment, using the new staging system. The investigators believe this treatment will provide the same effectiveness as the usual treatment, but decrease the side effects. The radiation doses, chemotherapy doses, and the type of surgical approaches that will be used in this treatment protocol have all been previously investigated. Previous research suggests that this can be done safely, but there has not been a study done basing treatment on the new staging system.
Sites
- Nebraska Methodist HospitalOmaha, Nebraska, United States